Posted by Michael Wonder on 13 Jan 2020
Novartis strikes deal with UK to provide cholesterol drug to high-risk patients
13 January 2020 - Pharmaceutical giant Novartis reached a deal with the U.K. to provide its late-stage cholesterol drug, inclisiran, to patients at high risk of a heart attack.
Pharmaceutical giant Novartis has reached a deal with the U.K. government to provide its late-stage cholesterol drug, inclisiran, to patients at high risk of a heart attack, the company announced Monday.
The drug, which is pending approval in the U.S., will be provided on a “population basis” to patients with atherosclerosis in the U.K. once it is tested in a large clinical trial and approved for use there. Atherosclerosis is a devastating heart disease in which plaque builds up inside arteries and can lead to serious problems, including heart attack, stroke or death.
